Direct intramyocardial plasmid vascular endothelial growth factor-A165gene therapy in patients with stable severe angina pectoris A randomized double-blind placebo-controlled study: The Euroinject One trial by Kastrup, Jens et al.
CD
E
T
A
P
J
D
V
M
C
S
V
g
a
o
¶
C
P
M
U
t
D
M
F
I
C
2
Journal of the American College of Cardiology Vol. 45, No. 7, 2005
© 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00
PLINICAL RESEARCH Clinical Trial
irect Intramyocardial Plasmid Vascular
ndothelial Growth Factor-A165 Gene
herapy in Patients With Stable Severe Angina Pectoris
Randomized Double-Blind
lacebo-Controlled Study: The Euroinject One Trial
ens Kastrup, MD,* Erik Jørgensen, MD,* Andreas Rück, MD,† Kristina Tägil, MD,‡
ietmar Glogar, MD,§ Witold Ruzyllo, MD, Hans Erik Bøtker, MD,¶ Dariusz Dudek, MD,#
iktor Drvota, MD,† Birger Hesse, MD,** Leif Thuesen, MD,¶ Pontus Blomberg, PHD,†
ariann Gyöngyösi, MD,§ Christer Sylvén, MD, FACC,† the Euroinject One Group
openhagen and Aarhus, Denmark; Vienna, Austria; Warsaw and Krakow, Poland; and Malmö and
tockholm, Sweden
OBJECTIVES In the Euroinject One phase II randomized double-blind trial, therapeutic angiogenesis of percutane-
ous intramyocardial plasmid gene transfer of vascular endothelial growth factor (phVEGF-A165) on
myocardial perfusion, left ventricular function, and clinical symptoms was assessed.
BACKGROUND Evidence for safety and treatment efficacy have been presented in phase I therapeutic
angiogenesis trials.
METHODS Eighty “no-option” patients with severe stable ischemic heart disease, Canadian Cardiovascular
Society functional class 3 to 4, were assigned randomly to receive, via the NOGA-MyoStar system
(Cordis Corp., Miami Lakes, Florida), either 0.5 mg of phVEGF-A165 (n  40) or placebo
plasmid (n  40) in the myocardial region showing stress-induced myocardial perfusion defects
on 99mTc sestamibi/tetrofosmin single-photon emission computed tomography.
RESULTS No differences among the groups were recorded at baseline with respect to clinical, perfusion,
and wall motion characteristics. After three months, myocardial stress perfusion defects did
not differ significantly between the VEGF gene transfer and placebo groups (38  3% and
44  2%, respectively). Similarly, semiquantitative analysis of the change in perfusion in the
treated region of interest did not differ significantly between the two groups. Compared with
placebo, VEGF gene transfer improved the local wall motion disturbances, assessed both by
NOGA (p  0.04) and contrast ventriculography (p  0.03). Canadian Cardiovascular
Society functional class classification of angina pectoris improved significantly in both groups
but without difference between the groups. No phVEGF-A165-related adverse events were
observed; however, NOGA procedure-related adverse events occurred in five patients.
CONCLUSIONS The VEGF gene transfer did not significantly improve stress-induced myocardial perfusion
abnormalities compared with placebo; however, improved regional wall motion, as assessed both
by NOGA and by ventriculography, may indicate a favorable anti-ischemic effect. This result
should encourage more studies within the field. Transient VEGF overexpression seems to be
safe. (J Am Coll Cardiol 2005;45:982–8) © 2005 by the American College of Cardiology
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.12.068Foundation
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wascular endothelial growth factor (VEGF) and fibroblast
rowth factor (FGF) have been used in clinical trials to
chieve better perfusion through angiogenesis in patients
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Manuscript received August 5, 2004; revised manuscript received November 27,
004, accepted December 6, 2004.ith chronic myocardial ischemia based on occlusive coro-
ary artery disease (1). After intracoronary infusion of
denoviral vectors encoding VEGF-A165 or FGF-4, con-
rolled trials reporting improved perfusion (2,3) and a trend
oward an increase in exercise capacity (4) have been
ncouraging. The efficacy of percutaneous intramyocardial
ransfer of VEGF encoding genes was explored in small
hase I/II studies. The results suggest clinical benefit and
mproved myocardial perfusion (5,6).
The aim of the present phase II randomized double-blind
lacebo-controlled multicenter study was to explore the
ngiogenic and clinical efficacy of direct percutaneous in-
ramyocardial plasmid phVEGF-A165 transfer in patients
ith severe coronary artery disease not appropriate foronventional revascularization.
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he study followed the recommendations of the Helsinki II
eclaration and was approved by the national ethics com-
ittees and the national drug agencies in the countries of
he six participating centers. All patients received verbal and
ritten information about the study and gave their written
nd signed informed consent. Centralized randomization
as performed according to international guidelines by the
ospital pharmacy at the Karolinska University Hospital.
umbered vials containing the plasmid (VEGF or placebo)
ere sent to each center. The code was not revealed until
fter all core lab analyses had been performed.
tudy protocol. Patients with symptomatic severe coronary
rtery disease that could not be revascularized further were
ncluded if adenosine stress 99mTc sestamibi/tetrofosmin
ingle-photon emission computerized tomography (SPECT)
howed a significant reversible perfusion defect as estimated
y two independent experienced observers. Patients also
ere included if they: 1) had at least one large epicardial
oronary artery with 70% stenosis remaining from which
ew collaterals/vessels could be supplied; 2) if they were
etween 18 and 75 years of age; and 3) if they had stable
ngina pectoris and a Canadian Cardiovascular Society
CCS) classification 3. We excluded patients with an
jection fraction 0.40, unstable angina pectoris, acute
yocardial infarction within the last three months, diabetes
ellitus with proliferative retinopathy, diagnosed or sus-
ected cancer, or chronic inflammatory disease. We also
xcluded premenopausal women.
Before inclusion, the following screening tests were per-
ormed: routine blood tests, plasma tumor markers (carci-
oembryonic antigen, prostate-specific antigen), urinary
ests, stools for occult blood (3), and chest X-ray. Prolif-
rative retinopathy was excluded by ophthalmoscopy in
atients with diabetes mellitus. A mammogram was per-
ormed in all women.
The prespecified end points at three months follow-up
ere: 1) the efficacy of the intramyocardial gene transfer,
easured by change in myocardial perfusion defects at stress
nd rest between inclusion and three-month follow-up
PECT studies (primary end point); 2) the safety of the
ercutaneous intramyocardial gene therapy, including risks
elated to the intramyocardial injection procedure and to the
EGF administration; 3) changes in wall motion distur-
Abbreviations and Acronyms
CCS  Canadian Cardiovascular Society
FGF  fibroblast growth factor
PCI  percutaneous coronary intervention
ROI  region of interest
SD/cord  standard deviation/cord
SPECT  99mTc sestamibi/tetrofosmin single-photon
emission computer tomography
VEGF  vascular endothelial growth factorances at NOGA endocardial mapping and contrast left 1entriculography; 4) CCS angina pectoris class; 5) the
requency of anginal attacks; 6) nitroglycerin consumption;
) patient score on the Seattle Angina Pectoris Question-
aire, and 8) exercise capacity (secondary end points).
urrent medication was not changed until follow-up was
ompleted. Additional clinical follow-up was performed six
onths after the intramyocardial injections. Signs of VEGF
xpression (Quantkine; R&D Diagnostics, Minneapolis,
innesota), inflammation in terms of C-reactive protein,
nd VEGF-induced recruitment of CD34 stem cells (flow
ytometry) were determined from successive blood determi-
ations.
lasmid VEGF-A165 and placebo plasmid. The plasmid
ontained a cytomegalovirus promotor/enhancer to drive
EGF-A165 expression. The placebo plasmid was identical to
he plasmid VEGF-A165 except for the VEGF-A165 gene,
hich had been cut out. Both plasmids were sequenced
ccording to Good Medical Practice (GMP) standards. The
lacebo plasmid did not contain any VEGF DNA. Both the
hVEGF-A165 and the placebo plasmid were produced at the
ene Therapy Center, Huddinge University Hospital (Stock-
olm, Sweden).
ingle-photon emission computed tomography and
OGA: electromechanical mapping of the left ventricle.
ingle-photon emission computed tomography studies were
onducted using a two-day protocol (500 to 700 MBq
9mTc-sestamibi or tetrofosmin at each study) (7) with
ombined low-level exercise-adenosine infusion during the
ourse of 4 to 6 min (0.14 mg/kg/min by infusion pump).
atients received 0.25 mg of nitroglycerin before the rest
can. Care was taken to perform the stress tests at inclusion
nd at the follow-up studies at the same time of day with
dentical exercise loads and cumulative adenosine doses.
With the NOGA system (i.e., NOGA mapping catheter
nd MyoStar injection catheter; Cordis, Johnson & John-
on, Miami Lakes, Florida), diagnostic three-dimensional
aps of the left ventricle were generated for the locally
easured voltage values (voltage map) and the systolic-
iastolic movement of the catheter tip (local linear shorten-
ng map) (8–10). There were two criteria for acceptance of
he NOGA map: at least three edited points at each of the
2 segments of the polar map and a minimum of 50 points
n the edited NOGA map.
ntramyocardial injections. On the basis of the localiza-
ion of the ischemic region assessed by SPECT and the local
inear shortening map, the region of interest (ROI) was
elineated on the NOGA map, and the injection catheter
as navigated into this area. Ten 0.3-ml intramyocardial
njections were given with the 8-F-sized MyoStar mapping
njection catheter within the delineated area with a total
ose of 0.5 mg phVEGF-A165 or placebo plasmid. The
njections were performed slowly (30 to 40 s) and only to
reas with a unipolar voltage5 mV and with a thickness of
he ventricle wall at echocardiography exceeding 6 mm.
Quality control of the injections included the following:
) the catheter’s tip perpendicular (30°) to the left ven-
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Intramyocardial VEGF Gene Therapy for Angiogenesis April 5, 2005:982–8ricular wall in two planes; 2) loop stability at the same level
s during the mapping procedure, if possible2 mm; and 3)
ctopic extraventricular beats at the exact moment of the
rotrusion of the injection needle into the myocardium.
nalysis of myocardial perfusion images. For semiquan-
itative and visual scoring core lab SPECT analysis, the
reated area (ROI) on the SPECT images was determined
n the basis of the NOGA polar plot images with the
elineated treated areas provided by each center for its own
atients. Because the NOGA treatment area did not com-
letely fit the SPECT-displayed reversible ischemic areas,
he usual SPECT segmental analysis was inadequate.
herefore, a three-point scoring system was used. First, the
everity of the reversible and irreversible perfusion defects at
aseline was scored as defects present or defects not present
s consensus readings by three experienced nuclear medicine
pecialists. Second, to assess changes between baseline and
hree-month follow-up studies, these were read together as
airs in a randomized order, which was blinded to the
eaders. Changes were scored as deterioration (1), un-
hanged (0), and improved (1). Two reasons that excluded
PECT maps were death during follow-up (n 1, placebo)
nd not interpretable as the result of poor image quality, as
ssessed by the core lab (n  4, placebo; n  1, VEGF).
Computer-based quantitative core lab SPECT analysis
as made on global left ventricular perfusion because the
OI could not be exactly determined as a result of the
ncertain concordance between SPECT and NOGA maps.
ransaxial files of the baseline and follow-up rest and stress
PECT images (provided in DICOM format from all
enters) were transferred to an image-analysis workstation
Onyx; SGI, Mountain View, California), and polar map
nalyses were performed using Munic-Heart software (Mu-
ich, Germany). The polar maps were then subdivided into
60 segments. The extent of severe (normalized tracer
ptake 50%) and moderate (normalized tracer uptake
etween 51% and 70%) and the summarized (sum of severe
nd moderate) extent of rest and stress-induced perfusion
efects were determined automatically and expressed as
ercentage of the entire myocardium.
nalysis of NOGA endocardial maps. In the quantitative
ore lab NOGA analysis, the ROI was delineated blinded
n the basis of the injection maps at baseline and at the
hree-month follow-up. Researchers performed blinded
uantitative assessments of the baseline and follow-up maps
s mean voltage and as local linear shortening values of the
OI and remote regions.
nalysis of digitized left ventricular angiography. At the
linded core lab analysis, ventricular volumes were digitized
nd a centerline was constructed midway between the two
ontours (Quantcor LVA, Siemens, Munich, Germany),
nd 100 equally spaced cords were drawn perpendicular to
he centerline between the contours. The normalized mo-
ion for each chord was displayed automatically (11). The
everity of the abnormality of the regional wall motion
ithin the left anterior descending, left circumflex coronary
m
ertery, and right coronary artery areas was computed as the
ean standardized motion of contiguous chords, and it was
ssessed as the average standard deviation per chord
SD/chord).
tatistical analysis. Sample size (n  80) with alpha
0.05 and beta  0.80 was calculated on the basis of
reviously reported results on myocardial perfusion after
ene therapy with phVEGF-A165 or phVEGF-C in open
hase I/II trials (5,12). The analysis was performed on the
asis of intention to treat. Changes within groups between
aseline and follow-up were tested using Wilcoxon’s two-
ided test for paired data and between groups with the
wo-sided Mann-Whitney U test or the exact Mann-
hitney U test. To assess differences between repeated
easures between the placebo and VEGF groups, two-way
nalysis of variance was used. A difference was considered
tatistically significant at p  0.05. Values are presented as
ean  SEM.
ESULTS
o demographic baseline differences were found between
he two groups (Table 1). The following are the treated
schemic areas for the patients in the VEGF and placebo
roups, respectively: anterior region (in 18% and 23%),
ateral (in 25% and 15%), posterior (in 33% and 30%), septal
in 13% and 13%), and mixed (in 11% and 19%).
afety data. Five procedure-related complications oc-
urred, with three occurring in the VEGF group. During
he injection procedure, one patient developed a pericardial
amponade, which was treated surgically without sequelae;
ne patient developed temporary loss of vision; and one
atient was successfully treated for sepsis. Within the
lacebo group, one patient developed third-degree atrioven-
ricular block and received a permanent pacemaker, and one
atient developed an ST-segment elevation myocardial
nfarction in the injection area. In addition, during diagnos-
ic NOGA before randomization at baseline, one patient
eveloped pericardial tamponade and died as the result of an
cute myocardial infarction during emergency surgery.
able 1. Baseline Demographic Data in Patients Treated With
ither Placebo or VEGF Gene Transfer
Placebo VEGF p Value
ge, yrs 61  2 61  2 0.97
ender, female/male 5/35 8/32 0.36
iabetes, n (%) 8 (20) 7 (18) 0.77
revious MI, n (%) 27 (68) 24 (60) 0.49
rior CABG, n (%) 30 (75) 31 (78) 0.79
rior PCI, n (%) 21 (52) 17 (42) 0.37
VEF (%) 62  11 61  11 0.68
CS class 3.0  0.3 3.1  0.3 0.55
ean  SEM. p value refers to differences between placebo- and VEGF transfer-
reated groups.
CABG  coronary artery bypass surgery; CCS  Canadian Cardiovascular Society
lassification of angina pectoris; LVEF  left ventricular ejection fraction; MI 
yocardial infarction; PCI  percutaneous coronary intervention; VEGF  vascular
ndothelial growth factor.
t
r
o
p
r
i
c
t
r
t
d
t
s
t
a
E
c
m
t
r
n
1
s
d
g
p
d
g
l
3
g
i
f
(
n
a
i
i
f
4
p
p
N
t
2
r
d
t
1
r
l
b
t
m
t
(
w
g
m
n
0
F
t
g
L
d
p
u
r
d
0
b
p
F
F
s
t
m
a
f
o
985JACC Vol. 45, No. 7, 2005 Kastrup et al.
April 5, 2005:982–8 Intramyocardial VEGF Gene Therapy for AngiogenesisSeventeen major cardiac complications occurred during
he six-month follow-up. In the VEGF group, four patients
equired percutaneous coronary intervention (PCI) because
f progression of stenosis at three months’ follow-up. Three
atients developed unstable angina pectoris, of which one
equired PCI. In the placebo group, acute myocardial
nfarction occurred in three patients, of which one died from
ardiogenic shock two months after treatment. Three pa-
ients developed unstable angina pectoris. One patient
equired PCI because of progression of stenosis at the
hree-month follow-up. One patient developed third-
egree atrioventricular block and received a pacemaker, and
wo patients were treated for heart failure. The independent
afety committee found no serious adverse events related to
he gene transfer. No patient developed clinical retinopathy,
nd no clinical or biochemical evidence of cancer was found.
fficacy data. MYOCARDIAL PERFUSION ANALYSIS. The
omputer-based quantitative analysis of size of severe (nor-
alized tracer uptake 50%) and moderate (normalized
racer uptake between 51% and 70%) perfusion defects at
est did not reveal significant differences between the groups
either at baseline nor at the three-month follow-up (Fig.
). The extent of the severe and moderate defects during
tress decreased nonsignificantly in both groups, and no
ifference at baseline and follow-up was found between the
roups (Fig. 1).
Also, the size of the global (severe plus moderate)
erfusion defects (normalized tracer uptake 70%) at stress
id not differ between the VEGF gene transfer and placebo
roups (expressed as percentage of the left ventricle: base-
ine, 48  3% and 49  2%, p  0.73; at three months,
8  3% and 44  2%, p  0.18, respectively), even if the
lobal perfusion abnormality during stress improved signif-
cantly (p  0.04, but not normalized) from baseline to
ollow-up in the VEGF group but not in the placebo group
p  0.22).
Semiquantitative analysis of the ROI in SPECT showed
o significant difference between the VEGF gene transfer
nd placebo groups in stress perfusion defects between
nclusion and three months’ follow-up, but a significant
mprovement was found from baseline to three-month
ollow-up after VEGF gene transfer, with improvement in
4% of the patients, no change in 41%, and impaired
erfusion in 15% (p  0.02). Corresponding fractions with
lacebo were 28%, 56%, and 16% (0.37), respectively.
OGA mapping. The number of the acquired points of
he ROI in the VEGF and placebo groups was 18  1 and
2  5 (total mapping points 100  5 and 102  5),
espectively. The mean voltage values of the ROI did not
iffer at baseline or at the three-month follow-up between
he groups (Fig. 2) and were close to normal (cut-off value
2.0 mV) (9). Similarly, the mean voltage values in the
emote myocardium did not differ between the groups. The
ocal linear shortening of the ROI was similarly impaired at
aseline (7.0  1.1% and 7.2  1.0% in the VEGF gene
ransfer and placebo groups, respectively). At the three- ronth follow-up, the local linear shortening was better in
he VEGF gene transfer group than in the placebo group
12.6 0.9% vs. 9.9 0.9%, p 0.04) (Fig. 2). Compared
ith the baseline, an improvement was observed in both
roups (VEGF, p  0.001; and placebo, p  0.05). The
ean local linear shortening of the remote myocardium did
ot change (VEGF, from 9.8  0.8% to 10.0  0.7%, p 
.35; placebo, from 9.3  0.7% to 10.6  0.5%, p  0.28).
igure 2 shows improved local linear shortening at the
hree-month follow-up in a patient treated with VEGF
ene transfer.
eft ventriculography. Baseline global ejection fraction
id not differ between the VEGF gene transfer group and
lacebo (61  1.3% and 62  1.3%, respectively) and was
nchanged at follow-up (61  1.5% and 59  1.6%,
espectively). The severity of local wall motion disturbance
id not differ at baseline (1.9  0.1 SD/cord and 2.1 
.1 SD/cord, respectively), whereas at follow-up it was
etter (p  0.03) after VEGF gene transfer compared with
lacebo (1.5  0.1 SD/cord and 2.0  0.2 SD/cord,
igure 1. Computer-based quantitative analysis of myocardial perfusion.
raction (%) of total segments (460) at polar map rest and stress
ingle-photon emission computed tomography with severe (normalized
racer uptake 50%; upper panel) and moderate perfusion defects (nor-
alized tracer uptake between 51% and 70%; lower panel) at baseline and
t follow-up in placebo (empty bars) and vascular endothelial growth
actor-treated groups (filled bars). No differences between the groups were
bserved. Values are given as mean  SEM.espectively) (Fig. 3).
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Intramyocardial VEGF Gene Therapy for Angiogenesis April 5, 2005:982–8linical outcome. At three-month follow-up, the CCS
ngina pectoris classification improved significantly in both
roups (VEGF, from 3.0  0.04 to 2.2  0.1, p  0.001;
lacebo, from 3.1  0.05 to 2.3  0.1, p  0.001), with no
ignificant difference between the groups and with no
urther change after six months (2.3  0.2 and 1.9  0.1,
espectively). At the three-month follow-up, no significant
ifferences between the VEGF- and placebo-treated groups
ere observed regarding peak exercise capacity (108  6 W
nd 112  8 W, p  0.69) with no further change after six
onths. Furthermore, at the three-month follow-up, no
ignificant differences between the VEGF and placebo
roups were observed regarding nitroglycerin consumption
igure 2. (Upper panel) Mean voltage and local linear shortening values
ere observed in voltage values. Significantly better local linear shortening
ars) versus the placebo group (empty bars) at the three-month follow-up w
rom a 56-year-old patient with chronic occlusion of the left circumflex cor
ascular endothelial growh factor-A165. Baseline registrations with injection
he larger figures show three-month follow-up registrations. No change w
bserved in the injection area.11  3 tablets/week and 10  4 tablets/week, p  0.15) and in the Seattle angina questionnaire scores (units):
hysical limitation (46  3 and 46  4, p  1.00), angina
tability (69  5 and 74  5, p  0.48), angina frequency
57  4 and 52  5, p  0.44), disease perception (57  4
nd 57  4, p  1.00), and treatment satisfaction (89  2
nd 83  3, p  0.06).
lasma VEGF-A, C-reactive protein, and circulating
D34 stem cells. Plasma VEGF-A increased in both
roups after treatment, reaching a peak value after one week
VEGF, from 69  14 ng/l to 140  30 ng/l, p  0.001;
lacebo, from 70  20 ng/l to 140  42 ng/l, p  0.001),
ut without a difference between the groups. CD34 stem
ells tended to be increased in the VEGF group three weeks
injected area at baseline and at the three-month follow-up. No changes
) in the injected area in the vascular endothelial growh factor group (filled
ted. Values are given as mean  SEM. (Bottom panel) NOGA mapping
artery. The patient received intramyocardial injection of plasmid encoding
s are shown in the small figure in the upper left corner of the NOGA map.
served in the voltage map, whereas improved local linear shortening wasof the
(LLS
as no
onary
point
as obfter treatment (VEGF, from 2.8  0.4 cells/106/l to 4.3 
0
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April 5, 2005:982–8 Intramyocardial VEGF Gene Therapy for Angiogenesis.6 cells/106/l, p 0.07; placebo, from 3.2 0.6 cells/106/l
o 3.7  0.4 cells/106/l, p  0.25), with no difference
etween the groups. C-reactive protein increased in the
EGF gene transfer group 24 h after treatment (VEGF,
rom 6.4  1.2 mg/l to 8.5  2.0 mg/l, p  0.03; placebo,
rom 6.2  1.1 mg/l to 7.8  1.9 mg/l, p  0.98) with no
ifference between the groups.
ISCUSSION
he Euroinject One trial is the first phase II multicenter,
ouble-blind, randomized placebo-controlled trial investi-
ating the therapeutic effect of percutaneous intramyocar-
ial plasmid VEGF gene transfer in patients with severe
table chronic myocardial ischemia. This study also is the
rst to use the gene transfer vehicle, a placebo plasmid, for
reatment in the control group.
The VEGF gene transfer did not significantly improve
he stress-induced myocardial perfusion abnormalities com-
ared with placebo. However, compared with the placebo
roup, both NOGA-determined left ventricular local linear
hortening and the regional wall motion of the treated
schemic area (assessed by left ventriculography) were sig-
ificantly better in the VEGF group at the follow-up.
The variability in myocardial perfusion at stress SPECT
mages was great in both groups. This variability was not
nticipated on the basis of previous studies (5,12) and could
e the result of both methodologic and biologic variability in
atients with diffuse severe myocardial ischemia, with a
ixture of scar tissue, hibernating myocardium, and still-
iable myocardium but without a capacity to improve after
evascularization.
In addition, the study revealed that the NOGA treatment
rea could only be approximately transferred to the SPECT
aps. Consequently, only visual semiquantitative SPECT
nalysis could be performed of the treatment area (ROI),
nd computer-based quantitative SPECT analysis could
nly be conducted as a global analysis of the perfusion
cintigraphic images in contrast to the exact analysis of the
reated area in the NOGA mapping. This discordance
etween SPECT and NOGA analysis might explain the
igure 3. Segmental ventricular function of the injected area expressed as
tandard deviations (SD)/cord as assessed from digitized left ventriculog-
aphy. Significantly better local wall motion was recorded in the vascular
ndothelial growth factor group (filled bars) versus the placebo group
empty bars) at the three-month follow-up. Values are given as mean 
EM.iscrepancies between the significant improvement in local dall motion and the nonsignificant improvement in perfu-
ion at follow-up.
The improved local linear shortening at NOGA and the
mproved angiographic wall motion might be due to im-
roved local perfusion of hibernating myocardium with a
hange to a more contractile cardiomyocyte phenotype.
owever, a criticism of the NOGA method is that the
schemic ROI was delineated on the baseline map, and
lthough the points of registration were similar at the
hree-month follow-up map, these points could not be
xactly the same as those at the baseline and thus might
ave included registrations from surrounding nonischemic
yocardium, a situation that resulted in a systematically
igher mean local linear shortening in the placebo group at
he follow-up investigation. Because this study used a
ouble-blind design, such a bias should not have influenced
he difference between placebo and VEGF gene transfer
reatments.
Advantages of the NOGA-MyoStar injection system are
hat it provides diagnostic means of studying the therapeutic
ffect in terms of effects on local left ventricle shortening
nd unipolar voltage as assessed on three-dimensional maps
nd the exact localization of the gene injection site, making
ossible the delivery of genes into the ischemic myocar-
ium. The criteria for a successful injection were developed
n pig experiments before initiation of the study, experi-
ents enabling us to conclude that 95% of the injections
ere successful with myocardial deposition of contrast agent
nd ink (unpublished observations) and a successful gene
xpression after intramyocardial injection of a VEGF-A165
ncoding plasmid (13). As a reflection of the injection
rauma, a transient increase in the plasma levels of
-reactive protein and VEGF was observed.
Some end points also were improved in the placebo group
1). The reason for the placebo effect is complex and
nclear. Some factors could be the special care and attention
he patient receives in a gene therapy trial, inflammation
nd scar formation after the NOGA procedure, or an
nflammatory reaction to the gene transfer vehicle.
Our study was designed with the main end points (stress
PECT, NOGA mapping, left ventricular angiography)
erformed at the three-month follow-up to avoid confound-
ng factors that might occur during a longer follow-up and
re associated with the natural course of coronary artery
isease in these severely ill and compromised patients. In
ur previous trial (12), we used 0.25 mg of phVEGF-A165
njection via thoracotomy. Because later feasibility was
eported also for 0.5 mg (14), we used 0.5 mg of plasmid
istributed in 10 injections, even if the highest effective dose
s not known.
The Kuopio Angiogenesis Trial (KAT) and Angiogenic
ene Therapy (AGENT) phase II trials (2,3) have been
ncouraging, suggesting that intracoronary adenoviral vec-
ors expressing VEGF or FGF-4 may have therapeutic
fficacy. Our results indicate that plasmid gene transfer via
irected percutaneous intramyocardial injection could be
o
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he risk of perforation of the left ventricle wall. Develop-
ent of the technique and softer catheters may minimize
his risk.
onclusions. Apart from catheter-related risks, percutane-
us intramyocardial plasmid gene transfer of VEGF is safe
nd well tolerated. Although no significant treatment effect
as observed at stress-induced perfusion defects at SPECT,
here was a trend for favorable anti-ischemic effects. These
ndings indicate that further studies are required to clarify
he future significance of VEGF gene therapy in the
reatment of patients with severe ischemic heart disease
ithout any option for conventional revascularization.
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PPENDIX
afety Committee: Jensen, Sweden; Thayssen, Denmark;
lein, Austria. SPECT Core Laboratory: Tägil, Eden-
randt, Sweden; Hesse, Buhl, Denmark; Gyöngyösi,
horsand, Sholeh Zamini, Austria. NOGA Core Labora-
ory: Gyöngyösi, Austria, Jørgensen, Denmark. Database
nd Safety Monitoring: Rück, Sweden.
he Euroinject One study sites, number of included
atients and co-investigators except authors: Sweden,
tockholm (n  7): Uchto, Nowak, Christensen, Lindvall;
enmark, Copenhagen (n  32): Carstensen, Gøtze, Ko-
oed, Johnsen. Denmark, Aarhus (n  10): Steen Nielsen,
øgaard, Hvidtfeld; Austria, Vienna (n  10): Strehblow,
perker, Maurer, Khorsand Graf, Sochor, Mundigler; Po-
and, Warsaw (n  11): Chojnowska, Kukula, Dabrowski,
itkowski, Chmielak, Teresiñska; Poland, Krakow (n 0): Rzeszutko, Heba, Hubalewska, Sowa-Staszczak.
